Teleflex (NYSE:TFX) Issues Earnings Results, Beats Expectations By $0.48 EPS

Teleflex (NYSE:TFX) released its quarterly earnings data on Thursday. The medical technology company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.48, FiscalAI reports. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The firm had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. During the same quarter in the previous year, the firm earned $3.73 earnings per share. The firm’s revenue was up 28.9% on a year-over-year basis. Teleflex updated its FY 2026 guidance to 6.900-7.200 EPS.

Here are the key takeaways from Teleflex’s conference call:

• Second-quarter results exceeded expectations, with pro forma adjusted constant-currency revenue growth of 4.7% and adjusted EPS of $1.76, supported by strong vascular and surgical performance.
• Teleflex lowered its 2026 revenue-growth outlook to 3.5%-4.5% from 4.5%-5.5%, primarily because integration of the Vascular Intervention acquisition is taking longer than expected and is now expected to continue through the second half of the year.
• The company raised 2026 adjusted EPS guidance to $6.90-$7.20 from $6.25-$6.55, reflecting share repurchases, lower projected interest expense, and a reduced tax-rate outlook, while maintaining an adjusted operating-margin outlook of approximately 19%.
• Teleflex closed the OEM divestiture for approximately $1.5 billion in proceeds and used much of the after-tax proceeds to repay $700 million of debt; it also plans to begin an additional $250 million accelerated share repurchase and remains committed to $1 billion of buybacks and $800 million of debt reduction.
• Innovation milestones included FDA approval of EZPLAZ freeze-dried plasma and continued progress for the Freesolve resorbable magnesium scaffold, including early completion of BIOMAG-II enrollment and commencement of the U.S. pivotal BIOMAG-III trial.

Teleflex Stock Performance

NYSE:TFX opened at $134.50 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.60 and a debt-to-equity ratio of 0.94. The company has a market cap of $5.95 billion, a P/E ratio of -5.78, a P/E/G ratio of 0.98 and a beta of 0.81. Teleflex has a fifty-two week low of $100.18 and a fifty-two week high of $145.00. The firm’s 50 day moving average is $131.72 and its two-hundred day moving average is $122.54.

Teleflex Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Friday, August 14th. Teleflex’s dividend payout ratio is presently -5.96%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on TFX shares. Mizuho lifted their price target on shares of Teleflex from $140.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Wells Fargo & Company lifted their price objective on Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research report on Wednesday, June 24th. Truist Financial restated a “hold” rating and issued a $143.00 price target (up from $135.00) on shares of Teleflex in a research report on Monday, May 11th. Finally, Royal Bank Of Canada raised Teleflex from a “sector perform” rating to an “outperform” rating and lifted their price target for the stock from $135.00 to $155.00 in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Teleflex has an average rating of “Hold” and a consensus target price of $149.80.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of TFX. AQR Capital Management LLC grew its stake in Teleflex by 478.1% during the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after buying an additional 1,956,811 shares during the period. State Street Corp raised its stake in shares of Teleflex by 1.5% in the 4th quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock valued at $180,470,000 after acquiring an additional 22,111 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Teleflex by 0.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company’s stock valued at $152,630,000 after acquiring an additional 5,051 shares during the period. Abrams Bison Investments LLC lifted its holdings in shares of Teleflex by 5.6% during the 4th quarter. Abrams Bison Investments LLC now owns 969,000 shares of the medical technology company’s stock valued at $118,257,000 after acquiring an additional 51,075 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Teleflex by 21.3% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 696,950 shares of the medical technology company’s stock valued at $85,056,000 after acquiring an additional 122,481 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex News Roundup

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex announced a $250 million accelerated share repurchase agreement. The program should reduce the company’s share count and may support per-share earnings and investor sentiment. Teleflex Launches $250 Million Accelerated Share Repurchase
• Positive Sentiment: Second-quarter revenue rose 28.9% year over year to $570.3 million, exceeding the $559.6 million consensus estimate. Adjusted EPS of $1.76 also beat expectations of $1.28, providing evidence of better-than-expected operating performance. Teleflex Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Teleflex raised or reaffirmed its fiscal 2026 adjusted EPS outlook at $6.90 to $7.20, above the $6.70 analyst consensus. Piper Sandler maintained an Overweight rating and increased its price target to $169 from $160, signaling additional potential upside. Piper Sandler Rating and Price Target
• Neutral Sentiment: Teleflex declared a quarterly dividend of $0.34 per share, payable September 30 to shareholders of record August 14. The dividend provides ongoing shareholder returns, though its approximately 1% yield is unlikely to be a major short-term catalyst.
• Negative Sentiment: GAAP diluted EPS from continuing operations fell to $0.96 from $1.54 a year earlier, while adjusted EPS declined from $3.73. Teleflex also reported a negative net margin, which may be weighing on the stock despite the quarterly earnings beat. Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.